Chairman

Dr Tony Evans, MAICD

Key skills: Specialist in managing collaborative research and industry drug development

Dr Evans has also been a director of Biolayer Corporation, Neurodiscovery, Coridon, Dendright, Promics, Q-Pharm and Spinifex. From 1988 to 1997 he worked in California, USA at Genentech then Onyx Pharmaceuticals.  On returning to Australia, he was appointed CEO and director of the CRC for Diagnostic Technologies and later, CEO and director of Xenome.  From 2008 to October 2011, he was CEO of Cancer Therapeutics CRC.

Dr Evans holds a BSc from the University of Sheffield, UK and a PhD from the Australian National University.  His early postdoctoral research included being Queen Elizabeth II Research Fellow in the Heidelberg Department of Medicine,Victoria, Alberta Heritage Post Doctoral Research Fellow at the University of Calgary and a Post Doctoral Research Fellow at The University of North Carolina.